Revisiting the Pharmacology of Unfractionated Heparin
- PMID: 30850987
- DOI: 10.1007/s40262-019-00751-7
Revisiting the Pharmacology of Unfractionated Heparin
Abstract
Unfractionated heparin (UFH) is a commonly used anticoagulant therapy for the acute treatment and prevention of thrombosis. Its short duration of action, reversibility of effect by protamine sulfate, and extensive clinical experience are some of the advantages that support its use. However, the choice of dose and dosing regimen of UFH remains challenging for several reasons. First, UFH has a narrow therapeutic window and wide variability in the dose-response relationship. Second, its pharmacodynamic (PD) properties are difficult to characterise owing to the complex multidimensional mechanisms of interaction with the haemostatic system. Third, the complex heterogeneous chemical composition of UFH precludes precise characterisation of its pharmacokinetic (PK) properties. This review provides a comprehensive mechanistic approach to the interaction of UFH with the haemostatic system. The effect of chemical structure on its PK and PD properties is quantitatively described, and a framework for characterisation of the dose-response relationship of UFH for the purpose of dose optimisation is proposed.
Similar articles
-
The Influence of Haemostatic System Maturation on the Dose-Response Relationship of Unfractionated Heparin.Clin Pharmacokinet. 2021 Apr;60(4):491-499. doi: 10.1007/s40262-020-00949-0. Epub 2020 Oct 31. Clin Pharmacokinet. 2021. PMID: 33128209
-
Development of a population pharmacokinetic-pharmacodynamic model of a single bolus dose of unfractionated heparin in paediatric patients.Br J Clin Pharmacol. 2016 Jul;82(1):178-84. doi: 10.1111/bcp.12930. Epub 2016 May 2. Br J Clin Pharmacol. 2016. PMID: 26972703 Free PMC article.
-
Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.Chest. 2004 Sep;126(3 Suppl):188S-203S. doi: 10.1378/chest.126.3_suppl.188S. Chest. 2004. PMID: 15383472
-
How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.Blood Coagul Fibrinolysis. 2016 Sep;27(6):605-14. doi: 10.1097/MBC.0000000000000469. Blood Coagul Fibrinolysis. 2016. PMID: 26656898 Review.
-
Heparin: Effects upon the Glycocalyx and Endothelial Cells.J Extra Corpor Technol. 2017 Sep;49(3):192-197. J Extra Corpor Technol. 2017. PMID: 28979043 Free PMC article. Review.
Cited by
-
Management of Therapeutic-intensity Unfractionated Heparin: A Narrative Review on Critical Points.TH Open. 2024 Oct 17;8(3):e297-e307. doi: 10.1055/a-2359-0987. eCollection 2024 Jul. TH Open. 2024. PMID: 39420916 Free PMC article. Review.
-
Individual variation in unfractionated heparin dosing after pediatric cardiac surgery.Sci Rep. 2020 Nov 10;10(1):19438. doi: 10.1038/s41598-020-76547-8. Sci Rep. 2020. PMID: 33173059 Free PMC article.
-
The Effect of Exercise on Pharmacodynamics and Pharmacokinetics of a Single Dose of Unfractionated Heparin-A Randomized, Controlled, Crossover Study.Clin Transl Sci. 2025 Jan;18(1):e70113. doi: 10.1111/cts.70113. Clin Transl Sci. 2025. PMID: 39783762 Free PMC article. Clinical Trial.
-
Effectiveness and safety of bivalirudin anticoagulation therapy in adult patients receiving extracorporeal membrane oxygenation: A systematic review and meta-analysis.Medicine (Baltimore). 2025 Aug 15;104(33):e42696. doi: 10.1097/MD.0000000000042696. Medicine (Baltimore). 2025. PMID: 40826747 Free PMC article.
-
The Influence of Haemostatic System Maturation on the Dose-Response Relationship of Unfractionated Heparin.Clin Pharmacokinet. 2021 Apr;60(4):491-499. doi: 10.1007/s40262-020-00949-0. Epub 2020 Oct 31. Clin Pharmacokinet. 2021. PMID: 33128209
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical